Adult Onset Still’s Disease

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
Cem Gabay, Bruno Fautrel, Jürgen Rech, François Spertini, Eugen Feist, Ina Kötter, Eric Hachulla, Jacques Morel, Thierry Schaeverbeke, Mohamed A Hamidou, Thierry Martin, Bernhard Hellmich, Peter Lamprecht, Hendrik Schulze-Koops, Delphine Sophie Courvoisier, Andrew Sleight, Eduardo Jorge Schiffrin

Annals of the Rheumatic Diseases Jun 2018, 77 (6) 840-847; DOI: 10.1136/annrheumdis-2017-212608
Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease
D Y Chen, J L Lan, F J Lin, T Y Hsieh, M C Wen

Annals of the Rheumatic Diseases Oct 2004, 63 (10) 1300-1306; DOI: 10.1136/ard.2003.013680
Methotrexate treatment in patients with adult onset Still’s disease—retrospective study of 13 Japanese cases
Takao Fujii, Masashi Akizuki, Hideto Kameda, Mami Matsumura, Michito Hirakata, Tadashi Yoshida, Taeko Shinozawa, Tsuneyo Mimori

Annals of the Rheumatic Diseases Feb 1997, 56 (2) 144-148; DOI: 10.1136/ard.56.2.144
Therapeutic innovation in adult-onset Still’s disease (and other rare inflammatory disorders): how to secure evidence-based medicine?
Philippe Guilpain, Alain Le Quellec, Alexandre Thibault Jacques Maria

Annals of the Rheumatic Diseases Dec 2018, 77 (12) 1699-1701; DOI: 10.1136/annrheumdis-2018-213106
Response to: the value of 18(F)-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study
Verena Schönau, Georg Schett

Annals of the Rheumatic Diseases Aug 2018, 77 (8) e53; DOI: 10.1136/annrheumdis-2017-212520

Log in using your username and password

Main menu

Log in using your username and password

You are here

Adult Onset Still’s Disease